Letting drug manufacturers put conditions on 340B drug discounts “would be akin to letting the fox guard the henhouse,” the U.S. Justice Department (DOJ) told federal appeals courts in Philadelphia and Washington, D.C., last night in a pair of filings in consolidated lawsuits over the government’s 340B contract pharmacy requirements.
“The bottom-line requirement is straightforward: if drug manufacturers want to be reimbursed for their drugs by the federally funded Medicaid and Medicare Part B programs, they also must sell their drugs to covered entities at a discounted price,” the government said in both legal briefs. “Drug manufacturers cannot add provisos to that straightforward statutory requirement.”
Letting drug manufacturers put conditions on 340B drug discounts “would be akin to letting the fox guard the henhouse,” the U.S. Justice Department (DOJ) told federal appeals courts in Philadelphia and Washington, D.C., last night in a pair of filings in consolidated lawsuits over the government’s 340B contract pharmacy requirements.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
